Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Gasperini

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
New oral drugs for multiple sclerosisClaudio Gasperini, S Ruggieri
Drug Design, Development and Therapy|August 14, 2012
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approachClaudio Gasperini, Serena Ruggieri
Expert Opinion on Emerging Drugs|December 14, 2011
Emerging oral drugs for relapsing-remitting multiple sclerosisClaudio Gasperini, Serena Ruggieri
Therapeutics and Clinical Risk Management|September 22, 2010
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsClaudio Gasperini, Serena Ruggieri, Carlo Pozzilli
Expert Opinion on Investigational Drugs|July 17, 2013
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini, Shalom Haggiag, Serena Ruggieri
Therapeutic Advances in Neurological Disorders|November 15, 2013
Efficacy and safety of laquinimod in multiple sclerosis: current statusShalom Haggiag, Serena Ruggieri, Claudio Gasperini
Therapeutics and Clinical Risk Management|April 8, 2014
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Expert Review of Neurotherapeutics|September 9, 2017
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Therapeutics and Clinical Risk Management|March 14, 2013
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimodClaudio Gasperini, Serena Ruggieri, Chiara Rosa Mancinelli, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2023
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
New oral drugs for multiple sclerosisClaudio Gasperini, S Ruggieri
Drug Design, Development and Therapy|August 14, 2012
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approachClaudio Gasperini, Serena Ruggieri
Expert Opinion on Emerging Drugs|December 14, 2011
Emerging oral drugs for relapsing-remitting multiple sclerosisClaudio Gasperini, Serena Ruggieri
Therapeutics and Clinical Risk Management|September 22, 2010
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsClaudio Gasperini, Serena Ruggieri, Carlo Pozzilli
Expert Opinion on Investigational Drugs|July 17, 2013
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini, Shalom Haggiag, Serena Ruggieri
Therapeutic Advances in Neurological Disorders|November 15, 2013
Efficacy and safety of laquinimod in multiple sclerosis: current statusShalom Haggiag, Serena Ruggieri, Claudio Gasperini
Therapeutics and Clinical Risk Management|April 8, 2014
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Expert Review of Neurotherapeutics|September 9, 2017
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Therapeutics and Clinical Risk Management|March 14, 2013
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimodClaudio Gasperini, Serena Ruggieri, Chiara Rosa Mancinelli, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2023
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Pageof 21